GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (OSL:TRMED) » Definitions » COGS-to-Revenue

Thor Medical ASA (OSL:TRMED) COGS-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA COGS-to-Revenue?

Thor Medical ASA's Cost of Goods Sold for the six months ended in Dec. 2024 was kr0.00 Mil. Its Revenue for the six months ended in Dec. 2024 was kr0.00 Mil.

Thor Medical ASA's COGS to Revenue for the six months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Thor Medical ASA's Gross Margin % for the six months ended in Dec. 2024 was N/A%.


Thor Medical ASA COGS-to-Revenue Historical Data

The historical data trend for Thor Medical ASA's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA COGS-to-Revenue Chart

Thor Medical ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Thor Medical ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Thor Medical ASA COGS-to-Revenue Calculation

Thor Medical ASA's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Thor Medical ASA's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thor Medical ASA  (OSL:TRMED) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Thor Medical ASA's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Thor Medical ASA COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA Business Description

Traded in Other Exchanges
Address
Karenslyst Alle 9C, Oslo, NOR, 0278
Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.

Thor Medical ASA Headlines

No Headlines